
    
      GHB16L2 intends to provide a novel vaccination for influenza virus infection. 80 healthy
      volunteers will be included at a ratio of 1:1 for GHB16L2 or placebo. GHB16L2 will be
      administered once on day 1. Follow-up visits will be performed on days 2, 8 and 29.
    
  